Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
How did MoneyWorks4me help subscribers to buy IEX at Rs. 193/ share 1 year before?
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Gujarat Themis Biosyn Ltd Stock Analysis

Small Cap
Evaluated by 412 users | BSE: 506879 | NSE: GUJTHEMIS |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 79.79%-369.62%200.09%115.77%79.15%48.05%33.43%34.83%64.96%50.05%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 8.728.430.231.432.635.738.841.185.190.6107
Y-o-Y Gr. Rt.-225.7%6.6%4%3.8%9.4%8.7%5.8%107.4%6.4%-
Adjusted EPS (Rs.) -2.160.693.113.33.213.012.664.3916.320.7725.83
Y-o-Y Gr. Rt.-NA350.7%6.1%-2.7%-6.2%-11.6%65%271.3%27.4%-
Book Value per Share (Rs.) -11.95-6.79-3.68-0.542.655.658.3412.7529.0448.1457.04
Adjusted Net Profit -2.514.54.84.74.43.96.423.730.238
Net Op. Cash Flow (Rs. Cr.) 1.90.54.32.73.92.85.60.70.610.5-
Debt to Cash Flow from Ops 6.1724.712.052.240.851.420.118.7612.920.29-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Gujarat Themis Biosyn Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 29.7%22.7%32.7%6.4%
Adjusted EPS NA45.3%98.4%27.4%
Book Value per Share 078.679.465.8
Share Price 47% 53.7% 149% 101.3%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 17.11-8.42-59.39-156.7305.1172.4638.0841.6177.9953.8149.12
Operating Profit Margin (%) -26.3412.8221.5420.8718.6616.9516.0917.9437.444.5347.01
Net Profit Margin (%) -28.793.5214.9415.2714.312.249.9715.5227.8133.3234.94
Debt to Equity -0.83-1.16-1.65-7.740.860.490.050.320.190.04-
Working Capital Days 16668565055787392144204-
Cash Conversion Cycle -74-44-54-52-47-26-22-192754-
Loading price chart...
Entity Percentage Holding
Promoters 74.99%
Institutions 0.03%
Non-Institutions 24.97%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Gujarat Themis Biosyn Ltd's earnings have grown by 45.3%, whereas share price has appreciated 53.7% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Gujarat Themis Biosyn Ltd share price has appreciated 47% annually (CAGR) over the past ten years.

Data is not available for this company.

Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.

The company has world-wide exports to satisfied customers, having customised facility for all products.

The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process.

Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.

The company has world-wide exports to satisfied customers, having customised facility for all products.

The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.

Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became India’s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.

Business area of the company

  • Pharmaceuticals & Drugs
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback